Aim: To evaluate the impact of antiplatelet therapy (APT)on the incidence of hepatocellular carcinoma (HCC) and mortality following its treatment. Methods: A systematic literature search was performed using PubMed and Cochrane Central Register of Controlled Trials Databases. Two HCC clinical settings were explored: (i) incidence, and (ii) death after any HCC treatment. Odds ratios (OR) and 95% confidence intervals (95%CI) were calculated to compare the pooled data between patients who received or did not receive APT. Results: A total of 20 studies were identified, of whom 15 focused on HCC incidence, including 2,685,009 patients, and five on post-treatment death, including 3281 patients. APT was associated with an overall reduced risk of HCC incidence (OR: 0.63; 95%CI = 0.51-0.79; p < 0.001) as well as of post-treatment mortality (OR: 0.54; 95%CI = 0.35-0.83; p = 0.006). Conclusions: Current data suggest that APT correlated with higher HCC incidence and poor overall survival following tumour treatment.

Lai, Q., De Matthaeis, N., Finotti, M., Galati, G., Marrone, G., Melandro, F., et al. (2023). The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 53(1), e13870 [10.1111/eci.13870].

The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma

Conti F.;Grieco A.;Guarino M.;Iavarone M.;Lenci I.;Manzia T. M.;Pompili M.;Rendina M.;Sacco R.;
2023-01-01

Abstract

Aim: To evaluate the impact of antiplatelet therapy (APT)on the incidence of hepatocellular carcinoma (HCC) and mortality following its treatment. Methods: A systematic literature search was performed using PubMed and Cochrane Central Register of Controlled Trials Databases. Two HCC clinical settings were explored: (i) incidence, and (ii) death after any HCC treatment. Odds ratios (OR) and 95% confidence intervals (95%CI) were calculated to compare the pooled data between patients who received or did not receive APT. Results: A total of 20 studies were identified, of whom 15 focused on HCC incidence, including 2,685,009 patients, and five on post-treatment death, including 3281 patients. APT was associated with an overall reduced risk of HCC incidence (OR: 0.63; 95%CI = 0.51-0.79; p < 0.001) as well as of post-treatment mortality (OR: 0.54; 95%CI = 0.35-0.83; p = 0.006). Conclusions: Current data suggest that APT correlated with higher HCC incidence and poor overall survival following tumour treatment.
2023
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/18 - CHIRURGIA GENERALE
Settore MEDS-06/A - Chirurgia generale
English
aspirin
clopidogrel
incidence
occurrence
survival
Lai, Q., De Matthaeis, N., Finotti, M., Galati, G., Marrone, G., Melandro, F., et al. (2023). The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 53(1), e13870 [10.1111/eci.13870].
Lai, Q; De Matthaeis, N; Finotti, M; Galati, G; Marrone, G; Melandro, F; Morisco, F; Nicolini, D; Pravisani, R; Giannini, Eg; Aglitti, A; Aliberti, C;...espandi
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Eur J Clin Investigation - 2022 - Lai - The role of antiplatelet therapies on incidence and mortality of hepatocellular.pdf

accesso aperto

Licenza: Non specificato
Dimensione 3.92 MB
Formato Adobe PDF
3.92 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/313485
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact